Professor Thomas K. Karikari is a Ghanaian neuroscientist whose research is contributing to one of the most important developments in modern medicine: the search for simple, reliable and affordable blood tests for Alzheimer’s disease.
His work focuses on biomarkers, which are measurable substances in the body that can reveal the presence or progression of a disease. In Alzheimer’s research, scientists study biomarkers linked to changes in the brain, including abnormal forms of tau and amyloid-beta proteins.
Karikari is a faculty member and researcher at the University of Pittsburgh School of Medicine in the United States. He has worked in psychiatry and clinical and translational science, with a research programme focused on Alzheimer’s disease, dementia and neurodegeneration. The University of Pittsburgh describes him as a specialist in the discovery, development, technical validation and practical application of blood biomarkers.
Early life and education
Karikari was raised in Ghana. During his childhood, he experienced the challenges faced by students in communities with inadequate teaching resources. At one point, a teacher left his school and was not replaced, forcing students to organise their own learning.
His early experiences helped shape his interest in education and science.
He studied Biochemistry at the Kwame Nkrumah University of Science and Technology in Kumasi. He subsequently earned a master’s degree in Pharmaceutical Biotechnology in the United Kingdom and completed a PhD at the University of Warwick. During his training, he also conducted research at Harvard Medical School.
Beginning of his research career
Karikari’s early scientific work focused on the biology of tau, a protein found in nerve cells. Under normal conditions, tau helps maintain the structure of brain cells. In some neurodegenerative diseases, however, tau becomes abnormal, clumps together and contributes to the destruction of healthy neurons.
His research examined how changes in tau are connected to diseases such as Alzheimer’s disease and frontotemporal dementia. He also became interested in the possibility of detecting these changes outside the brain.
For many years, researchers faced a major diagnostic challenge. The biological changes associated with Alzheimer’s can begin long before a person develops serious memory problems, yet the most accurate tests were often expensive, invasive or difficult to access.
The standard methods included brain imaging and the analysis of cerebrospinal fluid obtained through a lumbar puncture. These procedures can provide valuable information, but they are not always available in low-resource settings and may be difficult for patients to undergo.
Karikari asked whether a blood sample could provide similar information.
Research into blood biomarkers
His research has helped advance the study of blood-based biomarkers for Alzheimer’s disease. These tests seek to identify proteins or fragments of proteins released into the bloodstream as disease-related changes take place in the brain.
Among the main targets of this research are phosphorylated tau proteins, often referred to as p-tau. Elevated levels of certain forms of p-tau may indicate biological changes associated with Alzheimer’s disease.
Karikari and his collaborators have worked on developing methods that can detect these markers at very low concentrations. This requires highly sensitive laboratory techniques, careful validation and comparisons with established diagnostic methods.
The objective is not simply to produce a test that detects a protein. Researchers must also determine whether the test is accurate, whether it can distinguish Alzheimer’s disease from other neurological conditions and whether it works reliably in different populations.
Karikari’s research has involved identifying and validating blood markers that may help detect Alzheimer’s-related changes earlier and support clinical decision-making.
Why the work matters
A dependable blood test could make dementia assessment more accessible. It could help doctors decide which patients require further examination, enable earlier referral to specialists and improve participation in clinical trials.
It could also reduce the dependence on expensive scans and invasive procedures. This is particularly important for countries where specialised neurological services are concentrated in major cities or are beyond the reach of many families.
For Ghana and other African countries, the potential benefits are significant. Many patients with memory problems may not receive a formal diagnosis because of limited specialist services, cost, distance or public misunderstanding of dementia.
Karikari’s background gives his work a personal connection to the problem. He has spoken about how limited diagnostic capacity in Ghana influenced his interest in developing tools that could eventually benefit people in communities such as his own.
Recognition and awards
Karikari’s work has attracted recognition from the international scientific community. In 2025, he received a University of Pittsburgh Chancellor’s Distinguished Research Award for his contributions to Alzheimer’s disease and neurodegeneration research.
This year, he also received an Excellence in Scientific Research award at the Millennium Excellence Awards in the United States.
– Charles Wundengba
Reader comments